$155.95
▲ +0.7% Today
as of Aug 5, 16:53 ET
Last 30 days
Recent Press Releases & News
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary
Palvella Therapeutics Inc (PVLA) (Q2 2026) Earnings Call Highlights: Strong Phase 3 Data and ...
Overview
52-week range
$20
$151
100% of range
Avg surprise (last 3)
+11.5%
Avg reaction (last 2)
-6.7%
0% positive
Latest IV / EM
63%
EM ±10.5% · $155 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-1.20 | $-0.90 | -33.3% | -62.2% | -13.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.03 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.86 | $-0.78 | -10.3% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.74 | $-3.40 | +78.2% | — | -0.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.94 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.47 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-8.70 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $3.62 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-10M | $-9M | $-8M | — | $-5M | $-3M |
| Net income | $-16M | — | $-11M | $-9M | $-8M | — | $-7M | $-4M |
| EPS (diluted) | $-1.20 | — | $-1.03 | $-0.86 | $-0.74 | — | $-3.94 | $-2.47 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $206M | $58M | $64M | $70M | $76M | $84M | $19M | $20M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $263M | $59M | $67M | $74M | $79M | $88M | — | — |
| Total assets | $264M | $60M | $67M | $74M | $79M | $88M | $21M | $25M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $31M | $32M | $28M | $26M | $24M | $26M | — | — |
| Total equity | $232M | $28M | $39M | $48M | $56M | $63M | $-87M | $-81M |